CB2 Insights, a worldwide provider of predictive analytics tools, information-driven application and other solutions across the healthcare marijuana worth chain, will start trading on the Canadian Securities Exchange March six by way of a reverse takeover. It will trade below the ticker “CBII.”

Benzinga caught up with CEO Prad Sekar to discover a lot more about the firm and its debut.

The choice to go public is largely tied to the company’s clinical consolidation tactic, aimed at countering the fragmentation inside the U.S. clinical market place, Sekar stated. Going public will primarily offer CB2 Insights with a currency it can use to aid speed up the acquisition of clinics, he stated.

Cannabis clinics nonetheless have a incredibly viable spot in the market place, in certain in markets that are just beginning to adopt cannabis as a medicine,” the CEO told Benzinga. “We will now function to amass as quite a few strong…

Original Author Hyperlink click right here to study total story..